Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference

Rhea-AI Summary

Genelux (NASDAQ: GNLX) announced that Thomas Zindrick, President, CEO and Chairman, and Matt Pulisic, CFO, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 12:00 p.m. ET in New York.

A live webcast will be available during the event and an archived replay will be posted on the company's investor website at https://investors.genelux.com/.

WESTLAKE VILLAGE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board and Matt Pulisic, Chief Financial Officer, will participate in a fireside chat at the Piper Sandler 37^th Annual Healthcare Conference on Wednesday, December 3, 2025 at 12:00 p.m. ET in New York, NY.

A live webcast of the fireside chat can be found here. Following the live webcast, an archived replay will be available on the Company’s website https://investors.genelux.com/.

About Genelux Corporation

Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Olvi-Vec currently is being evaluated in two U.S.-based clinical trials: OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer; and, VIRO-25, a multi-center, randomized, open-label Phase 2 trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in non-small-cell lung cancer. Additionally, Olvi-Vec currently is being evaluated for dose selection in Olvi-Vec-SCLC-202, a China-based, multi-center, open label Phase 1b trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet in recurrent small-cell lung cancer. The core of Genelux's discovery and development efforts revolves around its proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com and follow us on X @Genelux_Corp and on LinkedIn.

Investor Contact

Austin Murtagh
Precision AQ
austin.murtagh@precisionaq.com

Media Contact

Ashley Murphy
Precision AQ
ashley.murphy@precisionaq.com

Source: Genelux Corporation

FAQ

When will Genelux (GNLX) present at the Piper Sandler 37th Annual Healthcare Conference?

Genelux will present on December 3, 2025 at 12:00 p.m. ET.

Who from Genelux (GNLX) will participate in the fireside chat on December 3, 2025?

Thomas Zindrick, President, CEO and Chairman, and Matt Pulisic, CFO, will participate.

How can investors watch the Genelux (GNLX) fireside chat webcast?

A live webcast will be available with an archived replay posted at https://investors.genelux.com/ after the event.

Where is the Piper Sandler 37th Annual Healthcare Conference presentation by Genelux (GNLX) being held?

The fireside chat will take place in New York, NY as part of the Piper Sandler conference.

Will a replay of the Genelux (GNLX) presentation be available if I miss the live webcast?

Yes, an archived replay will be available on the company's investor website after the live webcast.